Navigation Links
RoosterBio and GenCure Sign Multiple Agreements to Advance Regenerative Medicine Startups

RoosterBio Inc. and GenCure, both regenerative medicine manufacturing technology leaders, have locked into multiple agreements to help companies advance their innovations to clinical testing more rapidly than ever before. Companies across the regenerative medicine industry, ranging from synthetic biology companies that are gene editing therapeutic cells for advanced functionality in vivo, to pioneering medical device companies that bridge the regenerative capabilities of living cells with medical devices, have signed agreements to accelerate their path to clinical testing. These companies are leveraging RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems and rapid product and process development platform, and GenCure’s current Good Manufacturing Practices (cGMP)-compliant hMSC-focused manufacturing facility.

RoosterBio and GenCure’s one-of-a-kind industry partnership was established in 2017, marrying RoosterBio’s leading regenerative medicine manufacturing platform for hMSCs with BioBridge Global’s manufacturing (via GenCure) and testing capabilities. Leveraging this collaboration enables companies to shorten their cell therapy product and process development timelines, simplify technology transfer into cGMP manufacturing, and develop commercially viable cost structures for innovative cell and gene therapy products.

“These signed agreements illustrate how the regenerative medicine field is accelerating in both technology and development pace, promising multiple waves of novel therapeutic approaches cresting in the coming years," said RoosterBio Founder and Chief Product Officer Jon A. Rowley, PhD.

There were 743 documented advanced cell therapy clinical trials initiated globally in 2018 alone according to “The fields of synthetic biology & gene editing are evolving to take cellular therapies to the next level by bringing advanced controls to the complex therapeutic environments,” added Rowley. “As the medical device technology segment is rapidly moving towards incorporating living cells into next generation products, RoosterBio and GenCure’s customers are forward engineering their products in ways not possible just a few years ago, and rapid implementation in clinical testing to de-risk new business models and therapeutic approaches is of utmost importance to the field, and investors. The field is now seeing more rapid turnaround in the testing of new products using truly convergent technologies.”

Under the terms of of these newly signed agreements, RoosterBio will apply its breakthrough CliniControl™ hMSC manufacturing platform to be the preferred provider of their customer’s external development work for hMSC supply and expansion, including bioreactor scale up and industrialized large scale manufacturing unit operations. GenCure has completed the technology transfer of RoosterBio’s bulk hMSC expansion processes and and will be performing cGMP manufacturing and release testing of clinical doses of cells, and is prepared to support regulatory filings to reduce timelines, costs, and complexity of the regulatory process.

“Our joint collaboration with GenCure and our customers reflects the importance of strategically positioned technology platforms, cGMP manufacturing and testing, and therapeutic business models that are designed for rapid implementation,” said Dr. Rowley. “We are excited to see RoosterBio’s value propositions of radically simplifying hMSC product development, process development and clinical manufacturing being leveraged to move this field forward.”

Senior Vice President for BioBridge Global & Chief Operating Officer for GenCure Becky Cap said, “GenCure understands the challenges encountered when translating cellular therapies for clinical use, especially when it comes to cGMP-compliant manufacturing and testing.” She added, “Our specialized services in hMSC contract manufacturing will help smooth the transition for our customers.”

RoosterBio’s proprietary, clinically-relevant product portfolio manufactured by GenCure was introduced in 2017 under the CliniControl™ brand name with the promise to radically simplify multiple steps in therapeutic development, allowing product developers to remove years of time and millions of dollars from their development timelines. To date, CliniControl is the first hMSC products to be commercialized as off-the-shelf, cGMP-compliant working cell bank and bioprocess media systems. RoosterBio products are being used by several companies working with hMSCs in the gene editing, extracellular vesicles, tissue engineering, medical device, and cell therapy market segments.

Rowley added, “We’ve shown that our CliniControl products can uniquely deliver on the regenerative medicine industry needs and continue to drive unparalleled efficiencies and economies of scale in clinical and commercial hMSC manufacturing, helping our customers accelerate development of exciting new regenerative medicine products.”

About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit

About GenCure & BioBridge Global
GenCure is a subsidiary of BioBridge Global (BBG), a not-for-profit organization with a mission to save and enhance lives through the healing power of human cells. Through its subsidiaries – GenCure, QualTex Laboratories and the South Texas Blood & Tissue Center – BBG provides cells and tissues, cGMP-compliant manufacturing, testing services and blood management services to clients worldwide. For more information about GenCure, please visit For more information on BioBridge Global, please visit

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
2. Margot Connor, CEO, RoosterBio Inc., Frederick Innovative Technology Center, Inc expected graduate earns “Top 10” Technology Industry Award
3. RoosterBio Launches a Xeno-Free Bioreactor Feed to Streamline Cell Expansion & Efficiently Reach Billions of hMSCs
4. RoosterBio Inc. Unites with Manufacturing Innovation Institutes, Joining Manufacturing USA Network
5. Engineered by RoosterBio Inc.: Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
6. Designed by RoosterBio Inc.: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
7. RoosterBio Inc. Launches Industry’s First Ready-to-Print Stem Cell Product
8. Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology
9. GenCure partnering with H-E-B to celebrate World Marrow Donor Day with drives across San Antonio: Teams to recruit for the Be The Match registry at 30 H-E-B locations
10. Becky Butler Cap Named Chief Operating Officer of San Antonio-based GenCure: New Executive to Lead Regenerative Medicine Subsidiary of BioBridge Global
11. OAI Announces Multiple Orders for Advanced, Model 6000, Production Mask Aligners
Post Your Comments:
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont Nutrition & ... the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening relationships and ... which is supported through a partnership with “Ethiopia Invest”, will run through May ...
(Date:5/14/2019)... ... 14, 2019 , ... Gateway Genomics , a leading developer of prenatal ... to 5,000 square feet. , “This past year has seen exponential growth for ... CEO, Chris Jacob. “The SneakPeek At-Home test, which is mailed directly to our customers ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys ... Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography ... is estimated that 6.3 million Americans will have glaucoma, with black Americans having ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers from Ambry ... discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive ... and ovarian cancer (HBOC). , Jill S. Dolinsky, director of clinical ...
Breaking Biology Technology:
(Date:6/4/2019)... (PRWEB) , ... June 04, 2019 , ... ... today announced the appointment of Susan Murphy as the new President of Molecular ... Sciences?owned by Molecular Devices’ parent company, Danaher Corporation. , Since joining Molecular Devices ...
(Date:6/4/2019)... TORONTO (PRWEB) , ... June 04, 2019 , ... ... automate the search for salient features of seizure risk signals, usually based on ... neurologist-driven EEG interpretation remains the only acceptable diagnostic methodology due to the complexity ...
(Date:6/3/2019)... (PRWEB) , ... June 03, 2019 , ... Stay on ... biotech, medical device and food industries. Access to all webinars is free, so be ... relevant in your field! , Visit to see our upcoming webinars: ...
Breaking Biology News(10 mins):